Overview
NRXP market data
Price History
NRXP price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.34 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.04 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2,336.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.62 – $5.06 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $143.9M · P/B 10.13.
Company News
NRx Pharmaceuticals To Host Conference Call And Q&A Session On August 10 To Discuss FDA's Completion Of First-Cycle Review Of Its ANDA For Preservative-Free KetamineBenzinga · Aug 7, 2026, 8:03 PM
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10Benzinga · Aug 7, 2026, 6:19 PM
NRX Pharmaceuticals shares are trading higher after the company announced that the FDA completed its first-cycle review of its ANDABenzinga · Aug 7, 2026, 12:52 PM
NRx Pharmaceuticals Announces FDA Found No Major Deficiencies In Its First-Cycle Review Of ANDA For Its Preservative-Free KetamineBenzinga · Aug 7, 2026, 11:03 AM
8-K filing — NRX Pharmaceuticals, Inc. (NRXP)SEC EDGAR · Aug 7, 2026, 11:00 AM
NRx Pharmaceuticals Issues Statement In Response To Kadima Allegations, Citing Arbitration Over Non‑Acquisition By HOPE TherapeuticsBenzinga · Jun 25, 2026, 8:10 PM
NRx Pharma’s HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemBenzinga · Jun 25, 2026, 11:15 AM
NRX Pharmaceuticals Subsidiary ZETA SURGICAL Announces First Successful Patient Treatment Using Zeta TMS Navigation SystemBenzinga · Jun 23, 2026, 3:15 PM
NRx Pharma Announces FDA Approval Of Intermediate Population Expanded Access Protocol For Use Of NRX-101, Fixed Dose Combination Of DCS And Lurasidone For Augmentation Of Accelerated TMSBenzinga · Jun 22, 2026, 11:15 AM
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockBenzinga · Jun 3, 2026, 1:15 PM